Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.81 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.81 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.81 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.81 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | HTR1B | P28222 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5816463 | 0.90 | ADRA1D (0.67) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL9539641 | 0.83 | HTR1A (0.80) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| Hydrochloric Acid SCHEMBL7648139 | 0.82 | HTR1A (0.79) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL5815076 | 0.81 | HTR1A (0.84) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL5820560 | 0.81 | HTR1A (0.84) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL5899226 | 0.79 | HTR1A (0.79) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL8758360 | 0.78 | ADRA1D (0.64) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL9546953 | 0.77 | HTR1A (0.75) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL5820432 | 0.76 | HTR1A (0.74) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| Hydrochloric Acid SCHEMBL8758747 | 0.76 | ADRA1D (0.62) | HTR1AADRA1DADRA1AADRA1BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006088954-A1 | DIHYDROINDOLYL METHANONES AS ALPHA 1A/1D ADRENORECEPTOR MODULATORS FOR THE TREATMENT OF BENIGN PROSTATIC HYPERTROPHY AND LOWER URINARY TRACT SYMPTOMS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-24 | — | — | WO | claimed |
| US-20060183902-A1 | Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-17 | — | — | US | claimed |
| US-20060183902-A1 | Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183902-A1 | Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms | ADRA1D, ADRA1A, ADRB1 | HTR1A 37/4885ADRA1D 1/4885ADRA1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.